DAREON-NEC-1
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- NCT07544654 ↗
- Recruiting
- Boehringer Ingelheim
- Focused
We haven't built an HCP commentary report on DAREON-NEC-1 (obrixtamig, carboplatin and 1 more in Extrapulmonary Neuroendocrine Cancer (epNEC)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DAREON-NEC-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Extrapulmonary Neuroendocrine Cancer (epNEC)
- Interventions
- Obrixtamig; Carboplatin; Etoposide; Ventana DLL3 RxDx assay
- Arms
- Obrixtamig + carboplatin + etoposide · Experimental
- Carboplatin + etoposide · Active comparator
- Enrollment
- 390 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 10, 2026
- Primary completion
- Dec 13, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07544654 · updated Oct 28, 2026